HLB is taking control of changes of the future in various business fields, with
constant efforts and passion.
HLB initiates administration to the first patient in clinical combination study of Colorectal Cancer
Elevar Therapeutics announced that the first patient administration was initiated in clinical combination phase 1b/2 of Rivocernib and Lonsurf® (Taiho Pharma, Japan) to enter the Colorectal Cancer tertiary therapeutics market.
This study will first determine the dose of Rivocernib in combination with Lonsurf, and then evaluate the efficacy and safety of patients with Rivoceranib and Lonsurf® (monotherapy and combination therapy respectively) in Phase 2.
Clinical trial phase 1b to determine the doses of Rivocernib and Lonsurf® will be conducted in three US hospitals (Washington University School of Medicine, Vanderbilt, and Florida Cancer Specialists) and the number of hospitals will be added for phase 2.
HLB is now preparing for NDA after finishing pre-NDA meeting with FDA for Rivocernib's gastric cancer treatment and expanding the value of the anticancer drug through indication-expanding clinical trials such as primary liver cancer treatment and Adenoid Cystic Carcinoma.